S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
NYSE:NVRO

Nevro - NVRO Stock Forecast, Price & News

$36.68
+0.23 (+0.63%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$36.14
$37.25
50-Day Range
$35.60
$47.90
52-Week Range
$34.70
$78.90
Volume
495,977 shs
Average Volume
583,945 shs
Market Capitalization
$1.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.58

Nevro MarketRank™ Forecast

Analyst Rating
Hold
1.93 Rating Score
Upside/​Downside
48.8% Upside
$54.58 Price Target
Short Interest
Bearish
9.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.07mentions of Nevro in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.72) to ($2.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

643rd out of 1,054 stocks

Surgical & Medical Instruments Industry

67th out of 105 stocks


NVRO stock logo

About Nevro (NYSE:NVRO) Stock

Nevro Corp. engages in the provision of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.

Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Stock News Headlines

Piper Sandler Trims Nevro (NYSE:NVRO) Target Price to $37.00
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Nevro (NYSE:NVRO) Cut to Hold at StockNews.com
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
What 4 Analyst Ratings Have To Say About Nevro
See More Headlines
Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Company Calendar

Last Earnings
11/02/2022
Today
1/28/2023
Next Earnings (Confirmed)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
945
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.58
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+48.8%
Consensus Rating
Hold
Rating Score (0-4)
1.93
Research Coverage
14 Analysts

Profitability

Net Income
$-131,360,000.00
Pretax Margin
-1.80%

Debt

Sales & Book Value

Annual Sales
$386.90 million
Book Value
$8.70 per share

Miscellaneous

Free Float
34,438,000
Market Cap
$1.30 billion
Optionable
Optionable
Beta
0.86

Key Executives

  • D. Keith GrossmanD. Keith Grossman
    Chairman, President & Chief Executive Officer
  • Roderick H. MacLeod
    Chief Financial Officer
  • David Caraway
    Chief Medical Officer
  • Christopher Christoforou
    Vice President-Technical Operations
  • Stephen Smith
    Vice President-Information Technology













NVRO Stock - Frequently Asked Questions

Should I buy or sell Nevro stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 4 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings
or view top-rated stocks.

What is Nevro's stock price forecast for 2023?

14 Wall Street research analysts have issued 1-year price objectives for Nevro's stock. Their NVRO share price forecasts range from $31.00 to $95.00. On average, they predict the company's stock price to reach $54.58 in the next year. This suggests a possible upside of 48.8% from the stock's current price.
View analysts price targets for NVRO
or view top-rated stocks among Wall Street analysts.

How have NVRO shares performed in 2023?

Nevro's stock was trading at $39.60 at the start of the year. Since then, NVRO stock has decreased by 7.4% and is now trading at $36.68.
View the best growth stocks for 2023 here
.

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our NVRO earnings forecast
.

How can I listen to Nevro's earnings call?

Nevro will be holding an earnings conference call on Thursday, February 16th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) posted its quarterly earnings data on Wednesday, November, 2nd. The medical equipment provider reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. The medical equipment provider had revenue of $100.47 million for the quarter, compared to analyst estimates of $99.08 million. Nevro had a negative net margin of 2.01% and a negative trailing twelve-month return on equity of 40.89%.

What guidance has Nevro issued on next quarter's earnings?

Nevro updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $406.40 million-$406.40 million, compared to the consensus revenue estimate of $405.14 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.62%) and Exchange Traded Concepts LLC (0.09%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends
.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $36.68.

How much money does Nevro make?

Nevro (NYSE:NVRO) has a market capitalization of $1.30 billion and generates $386.90 million in revenue each year. The medical equipment provider earns $-131,360,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does Nevro have?

The company employs 945 workers across the globe.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com.

This page (NYSE:NVRO) was last updated on 1/28/2023 by MarketBeat.com Staff